Table 1.
Practice Name |
Total CKD Patients* |
eGFR < 30 |
White | African American |
Hispanic | Female | Age > 65 years |
---|---|---|---|---|---|---|---|
Pilot Site** | 1754 | 593 | 98% | 2% | 0% | 51% | 69% |
Study Site 1 | 132 | 51 | 99% | 2% | 0% | 58% | 74% |
Study Site 2 | 126 | 50 | 95% | 4% | 0% | 64% | 71% |
Study Site 3 | 861 | 248 | 99% | 1% | 0% | 62% | 82% |
Study Site 4 | 172 | 54 | 98% | 1% | 0% | 53% | 81% |
Study Site 5 | 221 | 58 | 100% | 0% | 0% | 62% | 82% |
Study Site 6 | 582 | 112 | 97% | 2% | 0% | 56% | 79% |
Study Site 7 | 116 | 46 | 99% | 1% | 0% | 51% | 82% |
Study Site 8 | 76 | 34 | 100% | 0% | 0% | 66% | 82% |
Grand Total | 4,040 | 1246 | 98% | 2% | 0% | 56% | 76% |
All patients >18 years with 2 eGFR measures <60 ml/min/1.73m2 more than 90 days apart, not on dialysis, with at least 1 visit at each respective study site;
One Geisinger nephrology clinic served only as Pre-Trial Intervention Refinement Site